ASCO
Refine Search
Biotechnology
Shares of Replimune closed up nearly 28% at $7.11 on Thursday after the company shared data on its oncolytic virus RP1 (vusolimogene oderparepvec), in combination with Bristol Myers Squibb’s Opdivo (nivolumab), 7 June 2024
Biotechnology
Gilead subsidiary Kite Pharma has announced updated four-year survival data from the ZUMA-3 study of Tecartus (brexucabtagene autoleucel). 5 June 2024
Biotechnology
Treos Bio, a biotech using data science and proprietary biomarkers to develop precision peptide immunotherapies, has presented results from its Phase II OBERTO-301 study. 4 June 2024
Biotechnology
US drugmaker AbbVie is keen not to be left behind in oncology’s antibody-drug conjugate (ADC) race. 4 June 2024
Biotechnology
French pharma major Sanofi released positive new data from the IMROZ Phase III study at the American Society of Clinical Oncology (ASCO) annual meeting. 4 June 2024
Biotechnology
Japanese pharma giant Takeda and Pfizer have announced positive results from the Phase III HD21 trial at the annual meeting of the American Society of Clinical Oncology (ASCO). 3 June 2024
Biotechnology
Faced with plenty of competition from other drugmakers at the 2024 American Society of Clinical Oncology (ASCO) meeting, Novartis has sought to show the strength of its cancer medicines with its latest data. 3 June 2024
Pharmaceutical
USA-based tumor drug resistance specialist Deciphera Pharmaceuticals today announced results from the company’s MOTION pivotal Phase III study of vimseltinib in patients with Tenosynovial Giant Cell Tumor TGCT) in an oral presentation at ASCO. 3 June 2024
Biotechnology
Positive results have been presented from the LAURA Phase III trial on AstraZeneca’s Tagrisso (osimertinib) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. 3 June 2024
Pharmaceutical
Eli Lilly has released updated data from its Phase I/II clinical trial evaluating olomorasib. 3 June 2024
Pharmaceutical
At the 2024 annual meeting of the American Society of Clinical Oncology (ASCO), Bristol Myers Squibb has announced promising results from the Phase III KRYSTAL-12 study. 3 June 2024
Biotechnology
US biotechs Gilead Sciences and Arcus Biosciences on Saturday announced longer-term efficacy and safety results from Arm A1 of the Phase II EDGE-Gastric study. 3 June 2024
Interview
With a steady flow of oncology results emerging from the ongoing ASCO meeting, a company such as Pierre Fabre, which does not have major data to present, might not usually claim the spotlight. 3 June 2024
Biotechnology
Researchers from UK-based biotech Immunocore Holdings shared new data at the American Society of Clinical Oncology (ASCO) meeting on Kimmtrak (tebentafusp-tebn), the first-ever treatment approved for metastatic uveal melanoma (mUM), showing there is treatment benefit for patients with stable disease and any confirmed tumor reduction. 3 June 2024
Pharmaceutical
US cancer-focussed firm Karyopharm Therapeutics presented updated exploratory subgroup analyses from the Phase III SIENDO study in patients with advanced or recurrent TP53 wild-type endometrial cancer at the American Society of Clinical Oncology (ASCO). 2 June 2024
Biotechnology
US healthcare giant Johnson & Johnson (NYSE: JNJ) released new data from the Phase III MARIPOSA study demonstrating the efficacy of first-line treatment with Rybrevant (amivantamab) in combination with lazertinib in non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. 1 June 2024
ASCO 2024
]S pharma giant Pfizer was trading more than 1% higher during Friday morning’s New York activity. 31 May 2024
Biotechnology
With the annual meeting of the American Society of Clinical Oncology (ASCO) now just days away, multiple large drugmakers have lifted the lid on data that they intend to present. 29 May 2024
Biotechnology
The annual meeting of the American Society of Clinical Oncology (ASCO) is set to commence on 2 June in Chicago, with the highly anticipated plenary session taking place on the Sunday. 22 May 2024
Pharmaceutical
Swiss cancer giant Novartis and German drugmaker Bayer are among the latest companies to lift the lid on upcoming data presentations at ASCO 2024. 17 May 2024
Pharmaceutical
One of the largest Phase III trials ever conducted in pancreatic cancer has shown that adding the oral drug capecitabine chemotherapy to gemcitabine prolongs survival without increased toxicity. 6 June 2016
Biotechnology
A Phase III trial of Johnson and Johnson (NYSE: JNJ) subsidiary Janssen’s Darzalex (daratumumab) in combination with Velcade (bortezomib) and dexamethasone (Dvd) in relapsed or refractory multiple myeloma patients has shown a 61% reduction in the risk of disease progression or death. 5 June 2016
Pharmaceutical
Swiss pharma giant Novartis has presented the first results from the Tasigna (nilotinib) treatment-free remission (TFR) clinical trial program at the 52nd American Society of Clinical Oncology (ASCO) annual meeting being held in Chicago. 5 June 2016
Pharmaceutical
A precision medicine approach using a patient’s individual tumor biomarkers to determine the best treatment leads to significantly better outcomes, according to data being presented at this year’s American Society of Clinical Oncology (ASCO) meeting. 4 June 2016
Pharmaceutical
German cancer specialist CellAct Pharma has presented positive new data on CAP7.1 for the treatment of biliary tract cancers at the Annual Meeting of the American Society for Clinical Oncology (ASCO). 3 June 2016
Pharmaceutical
German family-owned pharma major Boehringer Ingelheim has launched a trial to further investigate olmutinib (BI 1482694) as a treatment for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). 3 June 2016
Biotechnology
Nektar Therapeutics has entered into an agreement with the European subsidiary of Japanese drug major Daiichi Sankyo for Nektar's investigational drug therapy, Onzeald (etirinotecan pegol, NKTR-102). 1 June 2016
Biotechnology
Eliot Forster, who became chief executive of Immunocore in January 2015, speaks to The Pharma Letter’s Katie Osborne on why he is so excited about ImmTACs and how the company is working around the clock to get its lead product – IMCgp100 - to a group of patients with no other treatment options. 27 May 2016
Pharmaceutical
Top executives from pharma and biotech companies across the globe are gearing up for one of the industry’s most prestigious annual events. The 2016 annual meeting of the American Society of Clinical Oncology (ASCO) will bring together some thirty thousand professionals from around the world to discuss the latest research and advances in cancer care. 23 May 2016
Pharmaceutical
Patients with metastatic colorectal cancer are more likely to survive if their tumor originates on the left-side of the colon versus the right, a study has revealed. 19 May 2016
Pharmaceutical
Stem cell transplant should remain the preferred treatment for patients with multiple myeloma aged 65 and under, according to a new study. 18 May 2016
Biotechnology
Merck & Co’s Keytruda improves long-term survival rates in newly diagnosed and previously treated patients with advanced melanoma and might even offer a complete cure, according to the results of an early-stage study. 18 May 2016
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze